ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,780Medicare Part D Prescriptions Filled, Including Refills

Rank: 17 out of 586

$558K Total Retail Price of All Prescriptions

Rank: 14 out of 586

347 Patients Receiving at Least One Drug in Part D
78%Patients 65 Years and Older
40% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Utah
Lower avg

Schedule Two
Controlled Substances

17% of this provider’s 347 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

16% of this provider’s 347 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

3% of this provider’s 7,487 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$57 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

28 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Utah
SIMVASTATIN 459 369 1 1
HYDROCODONE-ACETAMINOPHEN 393 314 S3 2 5
LISINOPRIL 355 323 3 4
OMEPRAZOLE 348 270 4 3
LEVOTHYROXINE SODIUM 314 210 5 2
FUROSEMIDE 269 213 6 9
POTASSIUM CHLORIDE 260 203 7 14
METFORMIN HCL 259 188 8 6
HYDROCHLOROTHIAZIDE 199 181 9 10
LEVOXYL 192 168 10 70
SERTRALINE HCL 168 150 11 21
METOPROLOL SUCCINATE 150 140 12 19
AMLODIPINE BESYLATE 149 128 13 7
ZOLPIDEM TARTRATE 147 120 14 8
LISINOPRIL-HYDROCHLOROTHIAZIDE 138 79 15 16
CITALOPRAM HBR 130 93 16 12
OXYCODONE HCL-ACETAMINOPHEN 125 75 S2 17 55
MORPHINE SULFATE ER 111 93 S2 18 49
GABAPENTIN 101 57 19 11
METOPROLOL TARTRATE 98 86 20 26
MELOXICAM 87 77 21 25
LOSARTAN POTASSIUM 84 71 22 18
ATORVASTATIN CALCIUM 80 48 23 17
OXYCODONE-ACETAMINOPHEN 79 52 S2 24 78
FLUTICASONE PROPIONATE 74 31 25 28
POLYETHYLENE GLYCOL 3350 74 65 25 47
CELEBREX 74 74 25 44
IBUPROFEN 73 42 28 43
ADVAIR DISKUS 72 59 29 59
RISPERIDONE 70 45 30 46
NEXIUM 69 68 31 51
WARFARIN SODIUM 64 42 32 13
LANTUS 60 47 33 33
MIRTAZAPINE 59 40 34 64
DIOVAN 59 46 34 72
PROAIR HFA 57 47 36 58
SPIRONOLACTONE 56 50 37 76
GLIPIZIDE ER 55 44 38 121
CYMBALTA 54 28 39 29
ALENDRONATE SODIUM 54 53 39 23
QUETIAPINE FUMARATE 53 48 41 50
METOLAZONE 51 33 42 154
OXYCONTIN 51 39 S2 42 140
DONEPEZIL HCL 51 49 42 40
AZITHROMYCIN 50 42 45 36
CIPROFLOXACIN HCL 50 39 45 82
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.